• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤抑制因子BRCA1的结构与功能

Structure-Function Of The Tumor Suppressor BRCA1.

作者信息

Clark Serena L, Rodriguez Ana M, Snyder Russell R, Hankins Gary D V, Boehning Darren

机构信息

Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, 77550.

出版信息

Comput Struct Biotechnol J. 2012 Apr 1;1(1). doi: 10.5936/csbj.201204005.

DOI:10.5936/csbj.201204005
PMID:22737296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3380633/
Abstract

BRCA1, a multi-domain protein, is mutated in a large percentage of hereditary breast and ovarian cancers. BRCA1 is most often mutated in three domains or regions: the N-terminal RING domain, exons 11-13, and the BRCT domain. The BRCA1 RING domain is responsible for the E3 ubiquitin ligase activity of BRCA1 and mediates interactions between BRCA1 and other proteins. BRCA1 ubiquitinates several proteins with various functions. The BRCA1 BRCT domain binds to phosphoproteins with specific sequences recognized by both BRCA1 and ATM/ATR kinases. Structural studies of the RING and BRCT domains have revealed the molecular basis by which cancer causing mutations impact the functions of BRCA1. While no structural data is available for the amino acids encoded by exons 11-13, multiple binding sites and functional domains exist in this region. Many mutations in exons 11-13 have deleterious effects on the function of these domains. In this mini-review, we examine the structure-function relationships of the BRCA1 protein and the relevance to cancer progression.

摘要

BRCA1是一种多结构域蛋白,在很大比例的遗传性乳腺癌和卵巢癌中发生突变。BRCA1最常发生突变的三个结构域或区域为:N端RING结构域、外显子11 - 13以及BRCT结构域。BRCA1的RING结构域负责BRCA1的E3泛素连接酶活性,并介导BRCA1与其他蛋白质之间的相互作用。BRCA1使多种具有不同功能的蛋白质发生泛素化。BRCA1的BRCT结构域与具有特定序列的磷酸化蛋白结合,这些序列可被BRCA1和ATM/ATR激酶识别。对RING和BRCT结构域的结构研究揭示了致癌突变影响BRCA1功能的分子基础。虽然目前尚无外显子11 - 13编码氨基酸的结构数据,但该区域存在多个结合位点和功能域。外显子11 - 13中的许多突变对这些结构域的功能具有有害影响。在本综述中,我们研究了BRCA1蛋白的结构 - 功能关系及其与癌症进展的相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83e9/3962187/668dae9ebbe8/CSBJ-1-e201204005-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83e9/3962187/674391a4f2a2/CSBJ-1-e201204005-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83e9/3962187/30113e1e4310/CSBJ-1-e201204005-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83e9/3962187/8e4bbe4d3ce6/CSBJ-1-e201204005-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83e9/3962187/668dae9ebbe8/CSBJ-1-e201204005-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83e9/3962187/674391a4f2a2/CSBJ-1-e201204005-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83e9/3962187/30113e1e4310/CSBJ-1-e201204005-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83e9/3962187/8e4bbe4d3ce6/CSBJ-1-e201204005-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83e9/3962187/668dae9ebbe8/CSBJ-1-e201204005-g004.jpg

相似文献

1
Structure-Function Of The Tumor Suppressor BRCA1.肿瘤抑制因子BRCA1的结构与功能
Comput Struct Biotechnol J. 2012 Apr 1;1(1). doi: 10.5936/csbj.201204005.
2
Impact of RING and BRCT domain mutations on BRCA1 protein stability, localization and recruitment to DNA damage.RING 和 BRCT 结构域突变对 BRCA1 蛋白稳定性、定位和募集到 DNA 损伤部位的影响。
Radiat Res. 2010 Jul;174(1):1-13. doi: 10.1667/RR1290.1.
3
BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer.BRCA1及其易损的C端BRCT结构域:结构、功能、基因突变以及与乳腺癌和卵巢癌诊断与治疗的关联
Pharmaceuticals (Basel). 2024 Mar 4;17(3):333. doi: 10.3390/ph17030333.
4
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.与p53结合的53BP1 BRCT区域的结构及其与Brca1 BRCT结构的比较。
Genes Dev. 2002 Mar 1;16(5):583-93. doi: 10.1101/gad.959202.
5
Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.丝氨酸239位点上ATR相互作用蛋白的磷酸化介导了其与乳腺癌-卵巢癌易感蛋白1的相互作用及检查点功能。
Cancer Res. 2007 Jul 1;67(13):6100-5. doi: 10.1158/0008-5472.CAN-07-0369.
6
BRCA1 and Its Network of Interacting Partners.BRCA1 及其相互作用伙伴网络。
Biology (Basel). 2013 Jan 2;2(1):40-63. doi: 10.3390/biology2010040.
7
Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.乳腺癌1号基因(BRCA1)羧基末端(BRCT)结构域的磷酸肽结合特异性
J Biol Chem. 2003 Dec 26;278(52):52914-8. doi: 10.1074/jbc.C300407200. Epub 2003 Oct 24.
8
BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity.BRCA1 肿瘤抑制依赖于 BRCT 磷酸蛋白结合,而非其 E3 连接酶活性。
Science. 2011 Oct 28;334(6055):525-8. doi: 10.1126/science.1209909.
9
Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis.BRCA1与53BP1的BRCT结构域比较:生物物理分析
Protein Sci. 2004 Mar;13(3):617-25. doi: 10.1110/ps.03461404.
10
The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression.BRCA1的C末端(BRCT)结构域在体内与CtIP相互作用,CtIP是一种与转录抑制的CtBP途径相关的蛋白质。
J Biol Chem. 1998 Sep 25;273(39):25388-92. doi: 10.1074/jbc.273.39.25388.

引用本文的文献

1
Mutational spectrum of BRCA genes in Egyptian patients with breast cancer.埃及乳腺癌患者中BRCA基因的突变谱
Sci Rep. 2025 Jul 18;15(1):26067. doi: 10.1038/s41598-025-09810-5.
2
An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations.一种用于有效抑制致病性无义突变的工程化谷氨酸转运RNA。
Nucleic Acids Res. 2025 Jun 20;53(12). doi: 10.1093/nar/gkaf532.
3
Prevalence and spectrum of germline BRCA1 and BRCA2 mutations in multiethnic cohort of breast cancer patients in Brunei Darussalam.

本文引用的文献

1
BRCA1 and BRCA2: different roles in a common pathway of genome protection.BRCA1 和 BRCA2:在共同的基因组保护途径中扮演不同的角色。
Nat Rev Cancer. 2011 Dec 23;12(1):68-78. doi: 10.1038/nrc3181.
2
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.BRCA1 环功能对于肿瘤抑制是必需的,但对于治疗抵抗是可有可无的。
Cancer Cell. 2011 Dec 13;20(6):797-809. doi: 10.1016/j.ccr.2011.11.014.
3
Cancer. BRCA1, everything but the RING?癌症。BRCA1,除了 RING 一无所有?
文莱达鲁萨兰国多民族乳腺癌患者队列中种系BRCA1和BRCA2突变的患病率及谱系
PLoS One. 2025 Jun 18;20(6):e0312635. doi: 10.1371/journal.pone.0312635. eCollection 2025.
4
influences whole body metabolism in humanized mice.影响人源化小鼠的全身代谢。
Am J Physiol Endocrinol Metab. 2025 Jun 1;328(6):E979-E993. doi: 10.1152/ajpendo.00222.2024. Epub 2025 May 12.
5
BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview.BRCA1和BRCA2作为口腔鳞状细胞癌的预后标志物:一篇综述。
Front Oncol. 2025 Mar 28;15:1528822. doi: 10.3389/fonc.2025.1528822. eCollection 2025.
6
Breast cancer gene-1 (BRCA1) potentiates maladaptive repair after kidney injury.乳腺癌基因1(BRCA1)增强肾损伤后的适应性不良修复。
J Exp Med. 2025 Jun 2;222(6). doi: 10.1084/jem.20231107. Epub 2025 Mar 28.
7
Pathogenic variants in and genes associated with female breast and ovarian cancer in the Mexican population.与墨西哥人群中女性乳腺癌和卵巢癌相关的基因中的致病变异。
J Med Life. 2025 Jan;18(1):38-47. doi: 10.25122/jml-2024-0213.
8
Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors.低剂量DNA甲基转移酶抑制剂增强PARP抑制剂在同源重组修复缺陷肿瘤中的作用。
Breast Cancer Res. 2025 Jan 16;27(1):8. doi: 10.1186/s13058-024-01954-y.
9
Zinc and its binding proteins: essential roles and therapeutic potential.锌及其结合蛋白:重要作用与治疗潜力
Arch Toxicol. 2025 Jan;99(1):23-41. doi: 10.1007/s00204-024-03891-3. Epub 2024 Nov 7.
10
Benign polymorphisms in the BRCA genes with linkage disequilibrium is associated with cancer characteristics.具有连锁不平衡的BRCA基因中的良性多态性与癌症特征相关。
Cancer Sci. 2024 Dec;115(12):3973-3985. doi: 10.1111/cas.16364. Epub 2024 Oct 12.
Science. 2011 Oct 28;334(6055):459-60. doi: 10.1126/science.1214057.
4
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.BRCA1 和 BRCA2 基因突变与卵巢癌患者的生存、化疗敏感性和基因错配修复表型的关系。
JAMA. 2011 Oct 12;306(14):1557-65. doi: 10.1001/jama.2011.1456.
5
The role of PARP in DNA repair and its therapeutic exploitation.PARP 在 DNA 修复中的作用及其治疗性开发。
Br J Cancer. 2011 Oct 11;105(8):1114-22. doi: 10.1038/bjc.2011.382.
6
BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.BRCA1 肿瘤抑制作用是通过异染色质介导的沉默实现的。
Nature. 2011 Sep 7;477(7363):179-84. doi: 10.1038/nature10371.
7
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.好与恶的环:RING 指泛素连接酶在肿瘤抑制和致癌作用中的十字路口。
Nat Rev Cancer. 2011 Aug 24;11(9):629-43. doi: 10.1038/nrc3120.
8
BRCT domains: easy as one, two, three.BRCT 结构域:如此简单,易如反掌。
Cell Cycle. 2011 Aug 1;10(15):2461-70. doi: 10.4161/cc.10.15.16312.
9
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.CDK1 活性受抑制使 BRCA 功能正常的癌症对 PARP 抑制剂敏感。
Nat Med. 2011 Jun 26;17(7):875-82. doi: 10.1038/nm.2377.
10
BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters.BRCA1 通过泛素化拮抗孕激素作用,导致孕激素受体降解,并使靶启动子发生表观遗传沉默。
Cancer Res. 2011 May 1;71(9):3422-31. doi: 10.1158/0008-5472.CAN-10-3670.